Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$69.71M-10.6%-$63.02M+10.9%-$70.69M-26.1%-$56.05M-38.2%-$40.56M+12.6%
$845K+12.5%$751K+0.8%$745K+0.4%$742K+96.3%$378K+3.8%
$13.36M+272%$3.59M-3.2%$3.71M+12.1%$3.31M+44.5%$2.29M+18.4%
-$66.29M-12.7%-$58.79M-32.0%-$44.54M+18.3%-$54.53M-43.0%-$38.14M+21.3%
$0$35K-80.1%
$98K$88.4M+0.2%$88.25M+56.9%$56.25M+138%
$24.47M$73.02M
$30.64M-57.7%$72.4M+14,982%$480K$0-100%$73.12M+48,325%
-$36.03M$44.06M+25.5%$35.12M-61.5%$91.14M+147%
-$66.29M-12.7%-$58.79M-32.0%-$44.54M+18.3%-$54.53M-42.8%-$38.18M+21.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does MoonLake Immunotherapeutics generate?
MoonLake Immunotherapeutics (MLTX) generated -$224.2M in operating cash flow over the trailing twelve months.
What is MoonLake Immunotherapeutics's free cash flow?
After $343.0K of capital expenditures, MoonLake Immunotherapeutics's free cash flow was -$224.2M over the trailing twelve months, down 60.0% year over year.
Where does MoonLake Immunotherapeutics's cash flow data come from?
Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.